Back to discover
Disease

Leiomyoma

Late-stage therapeutic developmentEmerging research
2
Publications
15
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Major developments

Clinical trials

15 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
15
All trials
4
Active
11
Late-stage
6
Completed
Late-stage studies
Recently completed

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major themes2
  • Leiomyoma2
  • Genome-Wide Association Study1
Leading journals1
  • Nature communications2
Leading researchers8
  • Abdula F2
  • Adli M2
  • Buyukcelebi K2
  • Duval AJ2
  • Elkafas H2
  • Seker-Polat F2
  • Bulun SE1
  • Chen X1
Affiliations (unnormalised)3
  • Robert Lurie Comprehensive Cancer Center2
  • Feinberg School of Medicine Northwestern University1
  • Northwestern University Feinberg School of Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.